Bevacizumab for the Treatment of Non-Small Cell Lung Cancer Patients With Synchronous Brain Metastases

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-54513-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cases of Non-Small Cell Lung Cancer With Brain Metastases Treated With Bevacizumab in Our Hospital

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2016English

Survival of Patients With Non-Small Cell Lung Cancer and Brain Metastases

Clinical Oncology
Nuclear MedicineRadiologyImagingOncology
2011English

Therapeutic Strategy for Non‑small‑cell Lung Cancer Patients With Brain Metastases (Review)

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2013English

Bevacizumab in the Treatment of Non-Small-Cell Lung Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

Non-Small Cell Lung Cancer Brain Metastases and the Immune System: From Brain Metastases Development to Treatment

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2018English

S100B as a Biomarker for Brain Metastases in Patients With Non‑small Cell Lung Cancer

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2020English

Preface on “Emerging Treatment Options for Brain Metastases From Non-Small Cell Lung Cancer”

Translational Lung Cancer Research
Oncology
2016English

Efficacy of Chemotherapy in Patients With Asymptomatic Brain Metastases From Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2006English

18f-Fet PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non–Small Cell Lung Cancer

Clinical Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy